It seems like a "we're not in Kansas anymore" moment. The validity of Merck & Co., Inc.’s patents for its 16-year old blockbuster diabetes treatment Januvia (sitagliptin) were upheld by a US district court 29 September, bolstering market exclusivity for the drug until May 2027.
The decision is subject to appeal. Nevertheless, Merck’s victory over patent challenger Viatris Inc. was hailed as a big...